We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
- Authors
Jo, Seri; Signorile, Luca; Kim, Suwon; Kim, Mi-Sun; Huertas, Oscar; Insa, Raúl; Reig, Núria; Shin, Dong Hae
- Abstract
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wreaked havoc all over the world. Although vaccines for the disease have recently become available and started to be administered to the population in various countries, there is still a strong and urgent need for treatments to cure COVID-19. One of the safest and fastest strategies is represented by drug repurposing (DRPx). In this study, thirty compounds with known safety profiles were identified from a chemical library of Phase II-and-up compounds through a combination of SOM Biotech's Artificial Intelligence (AI) technology, SOMAIPRO, and in silico docking calculations with third-party software. The selected compounds were then tested in vitro for inhibitory activity against SARS-CoV-2 main protease (3CLpro or Mpro). Of the thirty compounds, three (cynarine, eravacycline, and prexasertib) displayed strong inhibitory activity against SARS-CoV-2 3CLpro. VeroE6 cells infected with SARS-CoV-2 were used to find the cell protection capability of each candidate. Among the three compounds, only eravacycline showed potential antiviral activities with no significant cytotoxicity. A further study is planned for pre-clinical trials.
- Subjects
SARS-CoV-2; DRUG repositioning; COVID-19; PROTEOLYTIC enzymes
- Publication
International Journal of Molecular Sciences, 2022, Vol 23, Issue 12, p6468
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms23126468